PCM
ANRO icon

Prelude Capital Management’s Alto Neuroscience ANRO Stock Holding History

Prelude Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,401
Closed -$45.8K – 1600
2025
Q3 		$45.8K Hold
11,401
– – ﹤0.01% 1108
2025
Q2 		$25.1K Sell
11,401
-2,244
-16% -$5.34K ﹤0.01% 971
2025
Q1 		$29.5K Buy
13,645
+1,400
+11% +$5.01K ﹤0.01% 1119
2024
Q4 		$51.8K Buy
+12,245
New +$76.4K ﹤0.01% 1145

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Prelude Capital Management's ANRO Position: Q4 2025 in Review

Prelude Capital Management sold out of Alto Neuroscience (ANRO) in Q4 2025, closing a stake of 11,401 shares — an estimated $45.8K sold.

Prelude Capital Management first reported a position in ANRO in Q4 2024 and held it in 4 quarters. The position peaked at $51.8K in Q4 2024. 97 funds tracked by Wall St. Rank hold ANRO as of Q4 2025.

  • Prelude Capital Management reported no remaining Alto Neuroscience position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 11,401 Alto Neuroscience shares in Q4 2025, an estimated $45.8K.
  • Prelude Capital Management first reported a position in Alto Neuroscience in Q4 2024 and held it in 4 quarters.
  • Prelude Capital Management's Alto Neuroscience position peaked at $51.8K in Q4 2024.
  • 97 funds tracked by Wall St. Rank held Alto Neuroscience as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.